Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.

ABSTRACT:

Background

Chronic angina is more common in patients with diabetes mellitus (DM) with poor glucose control. Ranolazine both treats chronic angina and improves glucose control.

Objectives

This study sought to examine ranolazine's antianginal effect in relation to glucose control.

Methods

The authors performed a secondary analysis of the RIVER-PCI (Ranolazine in Patients with Incomplete Revascularization after Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angina and incomplete revascularization following percutaneous coronary intervention were randomized to ranolazine versus placebo. Mixed-effects models were used to compare the effects of ranolazine versus placebo on glycosylated hemoglobin (HbA_1c) at 6- and

SUBMITTER: Fanaroff AC 

PROVIDER: S-EPMC5784418 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature